Despite confirmed BETi target engagement, RO6870810 failed to reduce tumor PD-L1 expression And suppressed Antitumor immunity, with only atezolizumab driving immune effector activation in the tumor microenvironment. This evidence concerns the gene CD274 and neoplasm.